作者
Zhiyi Chen,Alex Inague,Kamini Kaushal,Gholamreza Fazeli,Thamara Nishida Xavier da Silva,Ancély Ferreira dos Santos,Tasneem Cheytan,Florêncio Porto Freitas,Umut Yildiz,Lucas Gasparello Viviani,Rodrigo S. Abreu e Lima,Mikaela P. Pinz,Isadora Medeiros,Thiago Gerônimo Pires Alegria,Railmara Pereira da Silva,Larissa Regina Diniz,Simon Weinzweig,Judith Klein‐Seetharaman,Andreas Trumpp,Adriana Mañas,Robert J. Hondal,Matthias Fischer,Christoph Bartenhagen,Briana K. Shimada,Lucia A. Seale,Marietta Fabiano,Ulrich Schweizer,Luís Eduardo Soares Netto,Flavia Carla Meotti,Hamed Alborzinia,Sayuri Miyamoto,José Pedro Friedmann Angeli
摘要
Selenocysteine (Sec) metabolism is crucial for cellular function and ferroptosis prevention and has traditionally been thought to begin with the uptake of the Sec carrier selenoprotein P (SELENOP). Following uptake, Sec released from SELENOP undergoes metabolisation via selenocysteine lyase (SCLY), producing selenide, a substrate used by selenophosphate synthetase 2 (SEPHS2), which provides the essential selenium donor - selenophosphate - for the biosynthesis of the selenocysteine tRNA. Here, we report the discovery of an alternative pathway mediating Sec metabolisation that is independent of SCLY and mediated by peroxiredoxin 6 (PRDX6). Mechanistically, we demonstrate that PRDX6 can readily react with selenide and interact with SEPHS2, potentially acting as a selenium delivery system. Moreover, we demonstrate the presence and functional significance of this alternative route in cancer cells where we reveal a notable association between elevated expression of PRDX6 with a highly aggressive neuroblastoma subtype. Altogether, our study sheds light on a previously unrecognized aspect of Sec metabolism and its implications in ferroptosis, offering new avenues for therapeutic exploitation.